PTGDS Inhibitor Therapy for Oxidative Stress in Cataracts
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug treatments for age-related cataracts, such as lanosterol, are ineffective, and there is a lack of research using single-cell transcriptome sequencing to understand the molecular mechanisms of lens aging and opacity, leading to potential intraoperative and postoperative complications.
Innovation Solution
The use of a PTGDS inhibitor, specifically AT-56, is employed in the preparation of a drug to inhibit PGD2 production, thereby reducing oxidative stress and apoptosis in lens epithelial cells, thereby delaying and reversing cataract development.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical treatment is used for age-related cataracts, then the treatment effectiveness is improved, but the risk of intraoperative and postoperative complications increases
Solution Approach 1:
The patent applies preliminary anti-action by using a PTGDS inhibitor to prevent oxidative stress and protein aggregation before they can cause cataract formation or worsen existing cataracts. The inhibitor proactively blocks the pathological pathway (PGD2-mediated oxidative stress) that leads to lens opacity, thereby reducing the need for surgical intervention and associated complications.
2Reliability
If lanosterol is used for drug treatment of cataracts, then some clinical effect is achieved, but the drug has no significant effect on age-related nuclear cataracts
Solution Approach 1:
The patent applies parameter changes by switching from lanosterol to a PTGDS inhibitor, which targets a different molecular parameter (oxidative stress pathway via PGD2 inhibition) rather than relying on lanosterol's mechanism. This parameter change enables the drug to be effective on age-related nuclear cataracts where lanosterol failed, expanding the adaptability of the treatment.
3Measurement precision
If single-cell transcriptome sequencing is used to explore molecular mechanisms of lens aging, then research precision is improved, but there is currently no related research in current literatures
Solution Approach 1:
The patent applies preliminary action by using single-cell transcriptome sequencing to identify the PTGDS/PGD2 pathway as a key mechanism in lens aging and cataract formation before developing the drug. This preliminary research action established the molecular target (PTGDS) and validated it through in vitro and in vivo experiments, creating the foundation for the subsequent drug development without relying on existing literature.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
AT-56 effectively reduces cataract progression by inhibiting PGD2 synthesis, lowering ROS and MDA levels, and reducing apoptosis in lens epithelial cells, thus alleviating cataract severity.
Implementation Method 1
PTGDS inhibitor is AT-56... competitively inhibits production of PGD2 by occupying a catalytic site of PTGDS
Implementation Method 2
reducing oxidative stress and apoptosis in lens epithelial cells... lowering ROS and MDA levels
Data Source
Figure 1A~1B
Figure 1C
Figure 1D
AI summary
The use of a PTGDS inhibitor in the preparation of a drug for treating cataracts. AT-56 is an effective and selective PTGDS inhibitor, and competitively inhibits the generation of PGD2 by occupying a catalytic site of PTGDS, and PTGDS leads to oxidative stress damage of human lens epithelial cells by catalyzing the synthesis of PGD2, thereby promoting the occurrence and development of aging and opacity of a lens, so that AT-56 can effectively alleviate the level of cataracts by means of reducing apoptosis caused by oxidative stress damage.